Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

Figures & data

Table 1. Distribution of demographic findings according to patient group and control group.

	Schizophrenia (n = 53)	Controls (n = 37)	p
Gender (Females)	25 (47.2.0%)	16 (43.2%)	0.713
Age	36.09 ± 10.87	33.86 ± 10.86	0.341
Number of hospitalizations	2.84 ± 1.57	NA	–
The duration of disorder	8 (1-28)	NA	–
BMI (kg/m^2)	24.2 ± 2.00	NA	–

Continuous variables are expressed as mean ± SD or median (min-max). Student’s t-test was used.

Categorical variables are expressed as n (%).

NA (not applicable), SD (standard deviation).

Table 2. First and second generation antipsychotics in terms of chlorpromazine equivalent doses.

Name of the drug	Number of patients	Median (mg/day)	Minimum (mg/day)	Maximum (mg/day)
Amisulpride [25]	3	200	100	300
Aripiprazole [26]	4	266	200	400
Quetiapine [26]	5	1067	533	1333
Clozapine [24]	6	650	500	1000
Olanzapine [26]	3	400	500	1000
Paliperidone [24]	14	600	400	800
Risperidone [26]	14	400	200	600
Zuclopenthixol [25]	3	200	100	300

Table 3. Laboratory findings of schizophrenia and healthy controls groups.

	Schizophrenia (n = 53)	Controls (n = 37)	p
Secretagogin (µg/mL)	1.13 (0.55–10.30)	0.96 (0.11–13.15)	0.899
Fasting glucose (mg/dL)	89.53 ± 13.68	91.78 ± 7.88	0.059
Insulin mIU/mL	10.00 ± 7.16	10.26 ± 5.83	0.496
HOMA – IR	1.82 (0.27–13.72)	2.05 (0.34–6.26)	0.452

Continuous variables are expressed as mean ± SD.

Student’s t-test was used.

Abbreviations: Homeostasis Model Assessment of Insulin Resistance index (HOMA- IR).

Table 4. PANSS score to patients with schizophrenia.

	Schizophrenia
PANSS positive score	28.40 ± 4.19
PANSS negative score	22.04 ± 7.45
PANSS general psychopathology score	53.55 ± 10.94
PANSS total score	103.98 ± 19.08

Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. New York: John Wiley & Sons; 2018.

 Google Scholar

Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667. doi: 10.4088/JCP.v64n0607

 PubMed Web of Science ®Google Scholar

Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: comparing apples and oranges! Indian J Psychiatry. 2013;55:207–208. doi: 10.4103/0019-5545.105522

 PubMed Web of Science ®Google Scholar